Cord blood transplants (CBT) result in high rates of engraftment in patients transplanted because of inherited diseases even across marked HLA disparities, mostly in children, with less severe manifestations of GVHD than BM and PBSC transplants. Evaluation of engraftment potential of CBT based on early progenitor content is difficult due to their inaccurate quantification. Instead, post-thaw nucleated cell counts (Pt-NCC) are commonly used for this purpose. We have analyzed engraftment as a function of pre-freeze nucleated cell counts (Pf-NCC) in patients receiving CBT because of inherited diseases. We have observed median times to engraftment of 26 days or less, shortest times ranging 8 to13 days, late engraftment or graft failures tending to be associated with age Ͼ15 years and infusions of Ͻ3.7 × 10 
engraftment in patients transplanted because of neoplastic diseases, even across marked HLA disparities, manifestations of GVHD being less severe than expected in transplants from donors with similar differences in HLA antigens. General experience is that, compared to transplants using cells of other sources -bone marrow (BM) or peripheral blood (PB) -time to engraftment is longer for CBT. [1] [2] [3] [4] [5] [6] Ex vivo culture expansion is being investigated as a procedure to accelerate engraftment of CBT. [7] [8] [9] [10] Due to difficulties inherent to the quantification of hematopoietic progenitors defined by phenotypic or functional features in cord blood (CB), it has not been possible to define the minimum number of these cells required for a high probability of engraftment of CBT. Total nucleated cell counts (NCC) have been widely used to estimate the engraftment potential of CB collections, as it has been shown to somehow correlate with CD34
+ cell content, and several clinical studies have clearly shown that there is a relationship between engraftment and post-thaw NCC (Pt-NCC) of the infused units, related to body weight. [1] [2] [3] [4] [5] [6] We have performed an analysis of engraftment on a selected group of CBT reported to the Eurocord Registry to try to obtain reference data that could be apropriate to evaluate the engraftment time of CBT performed with culture-expanded CB cells. 6 We also have assayed simultaneous infusion to the same patient of unexpanded and expanded CB cells from different donors, a model that may allow us to evaluate the contribution of expanded CB cells to engraftment on the basis of the traceability of the engrafted cells by means of differentiating genetic markers.
Patients and methods

Retrospective analysis of CBT engraftment
For this analysis, CBT reported to the Eurocord Registry were selected on the basis of: (1) transplantation because of a neoplastic disease, as this implies maximized myeloablative and intensive immunosuppressive conditioning treatments, thus minimizing risk of rejection; and (2) to have achieved engraftment, or else to have survived more than 60 days after the CBT without evidence of autologous reconstitution, either spontaneous or as a result of reinfusion of autologous bone marrow. This was done to eliminate patients dying before they had a real opportunity for engraftment as many patients have received CBT in relatively poor conditions, as a last therapeutic resource. Pre-freeze NCC (Pf-NCC) was chosen for the analysis instead of Pt-NCC, that is, the number of cellular elements that are really infused, because: (1) Pt-NCC can not be known until the very moment of transplantation, thus not being available at the time of decision making on performing a CBT with an available unit; (2) the nature of the cellular elements that make up the Pt-NCC may vary widely from unit to unit as a result of varying degrees of damage inflicted on the process to cells of different kinds; and (3) it is possible that the Pf-NCC including all types of naturally occurring cells (granulocytes, monocytes, erythrocyte precursors and lymphoid cells), may have a closer correlation with the CB content on primitive hematopoietic progenitor cells than the cells counted in the postthaw material, often improperly referred to as 'mononuclear cells'. ANC Ͼ500/l for a minimum of 3 consecutive days was taken as evidence of engraftment and time to engraftment is the number of days after the CBT until the first day of sustained ANC Ͼ500/l. Time to platelet engraftment is the number of days after CBT until sustained counts Ͼ20 000/l without platelet transfusions. Engraftments occurring later than day +40 for granulocytes and/or later than day +100 for platelets were regarded as 'late engraftments'. Survival longer than 60 days after CBT without granulocyte engraftment was regarded as 'engraftment failure'. To facilitate statistical calculations these patients were assigned engraftment times Ͼ80 days for granulocytes and Ͼ180 days for platelets.
Double CBT
These have been performed as compassionate treatment in five adults with refractory AL, for whom no better treatment was available after patients' informed consent and approval by hospitals' ethical committees. All patients were conditioned with regimens that included TBI, CTX and ALG and in the early period after transplant they all received CsA and prednisone. Patients were 25 to 43 years old (median 29), their weight varying between 50 and 92 kg (median 60)
The best CB units available for the patients both in terms of cell content and HLA compatibility were infused immediately after thawing. Immediately afterwards, patients were given the cells resulting from 6 days culture of the CD34 + cells positively selected after thawing from the second best available CB unit. Cultures were done as previously described, using Teflon bags, static conditions and serum-free, stroma-free medium containing IL-3, SCF, TPO and FLT.3, 100 ng/ml concentration each.
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Results
Retrospective analysis of CBT engraftment
Out of the total 260 CBT (102 related and 158 unrelated) included in the Eurocord Registry until April 1998, 133 were eligible for our analysis, ages 1-45 years (median 7) and weights 6.5-70 (median 23). CB donors were related in 50 (ages 1 to 20 years, median 5, with only three patients older than 15) and unrelated in 83 (ages 1 to 45 years, median 9, 30 older than 15). Weight ranges were respectively 10 to 50 kg (median 19.8) and 6.6 to 87 (median 23) ( Table 1 ). The great majority of the related transplants were HLA identical, meanwhile the great majority of the unrelated had 1 or 2 HLA disparities in loci A, B or DR, generally defined by low resolution methods, which implies a greater degree of differences at molecular level.
The transplanted CB units had Pf-NCC in the range of 13.1 to 370 × 10 7 , median 117.2 (a figure close to the mean of CB collections), providing 0.97-55 × 10 7 Pf-NCC/kg (median 4.34). CB units transplanted to older patients were of higher Pf-NCC but they provided a lower Pf-NCC (Table  1) . Overall engraftment rate was 90%, 95% for the 100 pediatric patients, 76% for the 33 adults and 68% for the 22 adults receiving units with Ͻ3.7 × 10 7 Pf-NCC/kg. In all subgroups median time to engraftment was 26 days or less, shortest times to ANC Ͼ500/l being in the range of 8 to 13 days in the different subgroups. Overall median time to platelet engraftment was 48 days (Table 2) .
Scatter diagrams plotting time to engraftment vs Pf-NNC/kg of the infused units ( Figure 1) show that engraftment failures and delayed engraftments of platelets occur mainly in patients transplanted with units providing Ͻ3.7 ϫ 10 7 Pf-NCC/kg. However, the majority of transplants done with units providing between 3.7 ϫ 10 7 and 1 ϫ 10 7 Pf-NCC/kg (the lowest cell number infused) also engrafted and without delay. Plots of neutrophil and platelet engraftment times of CBT of more than and less than 3.7 ϫ 10 7 Pf-NCC/kg and percentile curves of actual engraftments similarly show that the main repercussion of lower cell dose and higher age is on rates of engraftment and on time to platelet engraftment (Figures 2 and 3) .
Double CBT
As shown in Table 3 , yields of cultures of the positively selected CD34
+ cells had marked differences. Expansion factors were lower in the last three cases, performed in 3 consecutive weeks, than in the first two done some 2 months earlier, that had expansion factors comparable to the preclinical assays. 11 No specific factors have been recognized as causes of these differences.
The freshly thawed CB units were 1 to 2 HLA Ag mm by low resolution methods and provided between 1.8 and 2.0 ϫ 10 7 Pf-NCC/kg (supposedly about 0.1 ϫ 10 6 CD34 + cells/kg). The expanded units were 1 to 3 HLA mm and provided 0.07 to 0.57 ϫ 10 6 CD34 + cells/kg, virtually free of lymphocytes. All products had viability higher than 90%.
Neutrophil engraftment to Ͼ500/l was achieved between days 17 and 27 by four of five patients. DNA of the unexpanded unit was first detected in PB and/or BM samples of all cases around day +10, when WBC was Ͻ200/l. At this time DNA from the expanded transplanted cells was also detected in four of five patients and in all cases patients' DNA was also present. In no patient was DNA of the expanded cells detected later, when the neutrophil counts increased to Ͼ500/l in four of five patients. In two patients no GVHD was observed. It was grade IV in one causing the patient's death; grade II rapidly responding to steroids in another; and very mild and spontaneously subsiding in the other one.
Discussion
Our retrospective analysis of CBT engraftment of unexpanded units showed that: (1) The probability of engraftment is high when the CB units provide a number of Pf-NCC/kg above a minimum that for adults is only provided by a lesser proportion on CB collections than for patients of pediatric age. (2) The median time to granulo- Pf-NCC/kg resulted in lower engraftment rates both of neutrophils and platelets and in substantial delay of platelet engraftment. These results may be an appropriate reference to evaluate results of clinical assays of CB transplants performed with ex vivo culture expanded cells. In some of these, the largest part of the transplanted CB unit has been infused immediately after thawing, meanwhile a smaller aliquot separated at the time of thawing has been subjected to in vitro cultures under exposure to several combinations of cytokines for 10-12 days before its delayed infusion. [8] [9] [10] [11] Another approach, used when the CB unit to be transplanted has been frozen in previously separated fractions, has been to anticipate initiation of the expansion culture of the smaller aliquot to infuse both fractions (unexpanded and expanded) at the same time. 7 Although in these assays substantial expansion has been achieved, mostly in terms of CFU-GM, time to neutrophil engraftment has not been significantly shorter than time to engraftment observed in CBT performed without previous expansion that we have analyzed. Moreover, the lack of differentiating genetic markers does not allow tracing of the cells first appearing in blood or marrow. Nevertheless, favorable short-term clinical course relative to their historical cases has been described by the investigators.
Bone Marrow Transplantation
Ex vivo cultured CB cells may have reduced capacity for in vivo homing and/or proliferation. This was suggested by results of our experimental work of transplantation of human CB cells to SCID/NOD mice, in which poorer early engraftment was observed for the ex vivo cultured cells using media containing different combinations of cytokines (IL3 + IL6 + SCF and IL11 + SCF + FL). 12 A more direct comparison of engraftment dynamics of expanded and unexpanded CB cells is offered by double transplants of freshly thawed CB cells and highly lymphocyte-depleted CD34 + cells obtained from a second, genetically different CB unit after in vitro expansion culture. Preliminary results of these assays suggest the expanded CB cells have only a limited capacity to survive in the recipient, as their DNA has not been traceable by the time of the ANC increase to Ͼ500/l, when the only donor DNA observed has been from the unexpanded cells, in full or mixed chimerisms.
This limited capacity of the cultured cells to survive in the recipient could be due to a relatively low number or to intrinsic lack of capacity for homing or proliferation induced by culture conditions. The possibility of rejection by immune reactive cells either of the patient or from the unexpanded CB unit seems unlikely because of the intensive immune suppression regimen the patients were receiving and the absence of signs of GVHD.
In conclusion, ex vivo cultured CB cells may have limited capacity to engraft in human recipients. Double transplants may be a suitable clinical model to evaluate the engraftment potential of different systems of culture expansion of purified CD34
+ CB cells, as no prohibitive adverse immunological effects have been observed. There is the possibility of immune tolerance being induced by the simultaneous infusion of the genetically different hematopoietic progenitors. Further clinical experience warrants consideration.
